Blood Glucose Determinations Differ in Plasma and Serum
|
By LabMedica International staff writers Posted on 05 Jul 2012 |
Blood glucose determination is one of the most common clinical diagnostic tests and accurate and precise measurement of blood glucose is of great importance in the diagnosis and management of diabetes.
The concentration of glucose in the blood will continue to decrease over time after phlebotomy because of glycolysis, which will occur in erythrocytes, white blood cells (WBCs), and platelets as these cells can continue to metabolize glucose.
Laboratory scientists at the University of Mysore, (Manasagangotri, India) investigated the effect of time and the method of processing of blood on the blood glucose levels. Blood from 30 different patients who came for routine blood glucose determination were used in the study. Whole blood was divided into three portions. One portion was allowed to clot. To the second portion, 2mg/mL sodium fluoride was added, and to the third portion, ethylene diamine tetra acetic acid (EDTA)–disodium salt was added.
Blood sugar was estimated using a blood sugar assay kit (Becton Dickinson, Bangalore, India). Optical Density (OD) of the colored complex was measured at 620 nm in an autoanalyzer. Blood sugar in these samples stored at room temperature was measured again after four hours and eight hours. The serum gave values lower than fluoride plasma by 1.15%. Although this difference was statistically significant, it may not be physiologically relevant. On storing the sample at room temperature for eight hours, the serum glucose value decreased by 8% and even fluoride plasma had 4.3% lower glucose.
The authors concluded that blood glucose should be determined within as short a time as possible after drawing the blood. The blood glucose values ranged from 76 to 410 mg/dL covering a wide range of blood glucose values that would be seen in any sample analysis. Serum may be a better sample for blood glucose determination particularly when there is a time delay in the measurement. If appropriate correction is applied, it may actually be a better sample than plasma. Moreover, many clinical analysis procedures require serum rather than plasma and therefore one single drawing of blood may suffice for even blood glucose estimation. The study was published online on May 14, 2012, in the Journal of Clinical Laboratory Analysis.
Related Links:
University of Mysore
Becton Dickinson
The concentration of glucose in the blood will continue to decrease over time after phlebotomy because of glycolysis, which will occur in erythrocytes, white blood cells (WBCs), and platelets as these cells can continue to metabolize glucose.
Laboratory scientists at the University of Mysore, (Manasagangotri, India) investigated the effect of time and the method of processing of blood on the blood glucose levels. Blood from 30 different patients who came for routine blood glucose determination were used in the study. Whole blood was divided into three portions. One portion was allowed to clot. To the second portion, 2mg/mL sodium fluoride was added, and to the third portion, ethylene diamine tetra acetic acid (EDTA)–disodium salt was added.
Blood sugar was estimated using a blood sugar assay kit (Becton Dickinson, Bangalore, India). Optical Density (OD) of the colored complex was measured at 620 nm in an autoanalyzer. Blood sugar in these samples stored at room temperature was measured again after four hours and eight hours. The serum gave values lower than fluoride plasma by 1.15%. Although this difference was statistically significant, it may not be physiologically relevant. On storing the sample at room temperature for eight hours, the serum glucose value decreased by 8% and even fluoride plasma had 4.3% lower glucose.
The authors concluded that blood glucose should be determined within as short a time as possible after drawing the blood. The blood glucose values ranged from 76 to 410 mg/dL covering a wide range of blood glucose values that would be seen in any sample analysis. Serum may be a better sample for blood glucose determination particularly when there is a time delay in the measurement. If appropriate correction is applied, it may actually be a better sample than plasma. Moreover, many clinical analysis procedures require serum rather than plasma and therefore one single drawing of blood may suffice for even blood glucose estimation. The study was published online on May 14, 2012, in the Journal of Clinical Laboratory Analysis.
Related Links:
University of Mysore
Becton Dickinson
Latest Clinical Chem. News
- Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
- Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
Channels
Molecular Diagnostics
view channel
New Library Normalization and Amplification Tools Support Oncology Sequencing
High-throughput next-generation sequencing (NGS) laboratories continue to grapple with uneven library pooling and amplification artifacts that can degrade variant calling accuracy and increase reruns.... Read more
Statistical Method Improves Detection of Low-Level Cancer DNA in Blood Samples
Blood-based assays are increasingly used to detect and monitor cancer, but many require relatively high fractions of circulating tumor DNA, limiting their utility when disease burden is low.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
Accurate classification of brain and spinal cord tumors increasingly depends on molecular profiling alongside histology, but access to such testing remains limited and results can take about two weeks.... Read more
IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Deficient DNA mismatch repair is an established predictive biomarker for response to immune checkpoint inhibitors, yet access to standardized assessment has varied across tumor types. Cancer remains the... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a progressive genetic condition, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD), and a cause of liver disease in both children... Read more








